MediWound (NasdaqGM:MDWD) FY Conference Transcript

MediWound FY Conference Summary Company Overview - Company: MediWound (NasdaqGM:MDWD) - Industry: Biotech, specifically focused on wound care and debridement products Key Points and Arguments Business Strategy - MediWound is a biotech company with a biologic technology validated in 14 clinical trials, with its first product approved by both FDA and EMA, and available in over 40 countries [4][5] - The company utilizes enzymatic technology to replace surgeries for severe burns and chronic wounds, with the first product achieving eschar removal in four hours [5] Market Opportunities - The addressable market for the second indication (EscharEx) is estimated at $2.5 billion, with ongoing pivotal phase three studies [6] - The company has collaborations with major players in the field to enhance treatment options for patients [6][14] Upcoming Catalysts - Significant catalysts expected in the next 6-12 months include: 1. Anticipated success in securing a significant portion of a ten-year BARDA contract [9] 2. Completion of a new manufacturing facility by the end of the year, which will alleviate current manufacturing bottlenecks [10] 3. An interim look at the phase three study results by mid-2026, which could indicate potential peak sales of $700 million [11] Clinical Trials and Collaborations - The phase three study for EscharEx is the largest clinical trial for venous leg ulcers in decades, with a high probability of success (90%) [18][19] - Collaborations with seven of the largest wound care companies to ensure the best treatment options for trial patients [16] Risk Management - The interim assessment aims to minimize risk and ensure the trial maintains a 90% probability of success [19][20] - Previous trials have shown a significant gap between MediWound's product and placebo, indicating strong potential for success [22] Manufacturing and Supply Chain - Discussions with the US government for funding a manufacturing facility, with plans to secure full funding [27] - The new facility in the US, along with existing facilities in Israel, will provide sufficient capacity for EscharEx's launch [27] Financial Position - Current cash position is $33 million, with an additional $30 million available through warrants [46] - Clinical trial costs are approximately $25 million, indicating a relatively stable financial situation [46] Market Performance of NexoBrid - NexoBrid has seen a 52% increase in revenue compared to the previous quarter, with strong adoption reported by burn centers [30] - Lessons learned from NexoBrid's commercialization will inform the launch strategy for EscharEx, which is expected to have a quicker uptake due to its replacement of existing products [31][32] Government Contracts and Future Developments - The new BARDA RFP includes stockpiling and development programs for NexoBrid, indicating continued government interest and investment [39][40] - The development of a room temperature stable formulation for NexoBrid is aimed at expanding its market reach [44][45] Additional Important Information - The company is prioritizing support for the US commercial market and the Israeli market due to current geopolitical circumstances [34] - The potential for a room temperature stable formulation could significantly enhance the product's usability in emergency situations [44][45]